Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Point Therapeutics |
---|---|
Information provided by: | Point Therapeutics |
ClinicalTrials.gov Identifier: | NCT00290017 |
This Phase 3 study will compare the efficacy of talabostat plus pemetrexed to pemetrexed plus placebo in patients with Stage IIIB/IV NSCLC who have failed a platinum-based chemotherapy regimen.
Condition | Intervention | Phase |
---|---|---|
Carcinoma, Non-Small-Cell Lung Lung Cancer Neoplasms, Lung Neoplasms, Pulmonary |
Drug: talabostat Drug: pemetrexed |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study |
Official Title: | A Phase 3, Randomized, Double-Blind, Multicenter Study of Talabostat and Pemetrexed vs. Pemetrexed and Placebo in Patients With Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | PTH-305 |
Study First Received: | February 9, 2006 |
Last Updated: | June 7, 2007 |
ClinicalTrials.gov Identifier: | NCT00290017 |
Health Authority: | United States: Food and Drug Administration |
Folic Acid Pemetrexed Thoracic Neoplasms Non-small cell lung cancer Respiratory Tract Diseases |
Lung Neoplasms Lung Diseases Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |
Antimetabolites Respiratory Tract Neoplasms Neoplasms Antimetabolites, Antineoplastic Neoplasms by Site Neoplasms by Histologic Type |
Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Therapeutic Uses Enzyme Inhibitors Folic Acid Antagonists Pharmacologic Actions |